Related Experiment Videos
Inhaled liposomal amikacin
1Division of Infectious Diseases, Department of Pediatrics, Hospital for Sick Children, University of Toronto 555 University Avenue, Toronto, Ontario, Canada M5G 1X8.
Abstract:
Arikace™ is a novel formulation of inhaled liposomal amikacin that can penetrate deep within airway secretions and within Pseudomonas aeruginosa biofilms, making it an attractive therapeutic option for the treatment of cystic fibrosis (CF) pulmonary infections. Initial Phase I and Phase II studies in CF patients with chronic P. aeruginosa infection demonstrated that Arikace™ was a safe drug that resulted in significant improvements in lung function after 14-28 days of treatment. Phase III studies of inhaled liposomal amikacin compared to tobramycin inhalation solution in CF patients with P. aeruginosa infection revealed a comparable increase in forced expiratory volume in 1 second at the end of three cycles. In addition, inhaled liposomal amikacin has other potential applications in the management of difficult-to-treat pulmonary infections. A Phase II trial is currently underway to study the use of Arikace™ for the treatment of recalcitrant nontuberculous mycobacterial lung disease.
Insights
Arikace, an inhaled liposomal amikacin formulation, shows promise for treating cystic fibrosis lung infections. Clinical trials indicate it is safe and improves lung function, comparable to existing treatments.
Area of Science:
- Pulmonary Medicine
- Infectious Diseases
- Pharmacology
Background:
- Cystic Fibrosis (CF) patients often suffer from chronic Pseudomonas aeruginosa infections.
- Effective delivery of antibiotics to biofilms and airway secretions in CF lungs remains a challenge.
- Amikacin is an aminoglycoside antibiotic with activity against P. aeruginosa.
Purpose of the Study:
- To evaluate the safety and efficacy of Arikace™, an inhaled liposomal amikacin formulation, for CF pulmonary infections.
- To compare Arikace™ to tobramycin inhalation solution in CF patients.
- To explore potential applications of Arikace™ in other difficult-to-treat lung infections.
Main Methods:
- Phase I, II, and III clinical trials were conducted in CF patients with chronic P. aeruginosa infections.
- Studies involved administration of inhaled liposomal amikacin (Arikace™).
- Lung function was assessed, including forced expiratory volume in 1 second (FEV1).
Main Results:
- Phase I and II studies demonstrated Arikace™ safety and significant lung function improvements after 14-28 days.
- Phase III trials showed Arikace™ achieved comparable lung function increases to tobramycin inhalation solution.
- A Phase II trial is ongoing for nontuberculous mycobacterial lung disease.
Conclusions:
- Inhaled liposomal amikacin (Arikace™) is a safe and effective option for CF patients with P. aeruginosa infections.
- Arikace™ demonstrates comparable efficacy to tobramycin inhalation solution.
- Arikace™ holds potential for treating other challenging pulmonary infections, including nontuberculous mycobacterial disease.